Takeda Pharmaceutical Company Limited
TAKWI
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 7.55B | 7.66B | 6.91B | 7.50B | 7.91B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.55B | 7.66B | 6.91B | 7.50B | 7.91B |
| Cost of Revenue | 2.58B | 2.66B | 2.45B | 2.73B | 2.65B |
| Gross Profit | 4.97B | 5.00B | 4.46B | 4.77B | 5.26B |
| SG&A Expenses | 1.72B | 1.77B | 1.94B | 1.77B | 1.80B |
| Depreciation & Amortization | 891.10M | 895.50M | 895.87M | 461.29M | 934.19M |
| Other Operating Expenses | 109.33M | 41.76M | -598.86M | 958.94M | -298.11M |
| Total Operating Expenses | 6.39B | 6.37B | 6.10B | 7.04B | 6.28B |
| Operating Income | 1.15B | 1.29B | 807.22M | 458.21M | 1.64B |
| Income Before Tax | 191.04M | 1.04B | -704.08M | 173.16M | 803.13M |
| Income Tax Expenses | 270.58M | 182.45M | -27.57M | 16.87M | 183.44M |
| Earnings from Continuing Operations | -79.54M | 860.47M | -676.51M | 156.29M | 619.69M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -488.20K | -249.30K | -374.00K | -301.60K | -410.40K |
| Net Income | -80.03M | 860.22M | -676.88M | 155.99M | 619.28M |
| EBIT | 1.15B | 1.29B | 807.22M | 458.21M | 1.64B |
| EBITDA | 2.41B | 2.55B | 1.45B | 1.68B | 2.93B |
| EPS Basic | -0.05 | 0.55 | -0.43 | 0.10 | 0.39 |
| Normalized Basic EPS | 0.35 | 0.42 | 0.26 | 0.08 | 0.52 |
| EPS Diluted | -0.05 | 0.54 | -0.43 | 0.10 | 0.38 |
| Normalized Diluted EPS | 0.35 | 0.42 | 0.26 | 0.08 | 0.51 |
| Average Basic Shares Outstanding | 1.58B | 1.56B | 1.58B | 1.59B | 1.58B |
| Average Diluted Shares Outstanding | 1.58B | 1.59B | 1.58B | 1.59B | 1.61B |
| Dividend Per Share | 0.68 | -- | 0.64 | 0.00 | 0.66 |
| Payout Ratio | -74.45% | 116.94% | -9.44% | 611.42% | 9.99% |